Update shared on04 Aug 2025
Fair value Decreased 15%Bora Pharmaceuticals’ consensus price target has been notably reduced, likely reflecting a slight decline in its future P/E ratio while profit margins remain stable, resulting in a revised fair value of NT$813.95.
What's in the News
- Completed share buyback of 36,000 shares (0.26%) for TWD 23.71 million.
- Approved amendment of the article of incorporation at AGM.
- Upcoming board meeting to approve 2025 Q1 consolidated financial statements.
Valuation Changes
Summary of Valuation Changes for Bora Pharmaceuticals
- The Consensus Analyst Price Target has significantly fallen from NT$1002 to NT$813.95.
- The Future P/E for Bora Pharmaceuticals has fallen slightly from 22.55x to 21.96x.
- The Net Profit Margin for Bora Pharmaceuticals remained effectively unchanged, at 15.88%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.